p53
Lamassu Biotech Garners FDA Clearance to Start Phase I MDM2 Therapy Trial in p53-Wildtype Tumors
The firm previously received a $2.05 million NIH grant to support development of SA53-OS in p53-wildtype sarcomas.
A Wistar Institute team found that two hypomorphic p53 variants in separate domains of that gene generate a shared gene expression signature in certain African populations.
Elicio Receives $2.8M Grant for Cancer Vaccine Development
The company will use the grant to develop vaccines targeting BRAF V600E and p53 hotspot mutations in solid tumors.
Aileron Therapeutics Pivots to Breast Cancer Development for ALRN-6924 After NSCLC Miss
Aileron believes an improved protocol for its Phase Ib breast cancer trial can show benefits for its chemoprotective drug after it failed to beat placebo in NSCLC.
PMV Pharmaceuticals Studying p53 Y220C Reactivator With Merck's Keytruda in Phase I/II Trial
In a new arm in the ongoing PYNNACLE trial, PMV will explore the safety and preliminary efficacy of the combination in p53 Y220C-mutated advanced solid tumor patients.
Jul 13, 2022
Aug 14, 2020
Jul 13, 2020